<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01521481</url>
  </required_header>
  <id_info>
    <org_study_id>AR HSG 03 2010</org_study_id>
    <nct_id>NCT01521481</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided Inguinal Field Block (Genitofemoral, Iliohypogastric and Ilioinguinal Nerve Block) for Inguinal Hernia Surgery</brief_title>
  <acronym>U-IFB</acronym>
  <official_title>Analgesic Efficacy of Ultrasound-guided Inguinal Field Block (Genitofemoral, Iliohypogastric and Ilioinguinal Nerve Block) for Inguinal Hernia Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera San Gerardo di Monza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the analgesic efficacy of an ultrasound-guided
      inguinal field block (block of the genitofemoral, iliohypogastric and ilioinguinal nerve).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inguinal hernia repair accounts for 10-15% of all operations in general surgery. Moderate to
      severe pain can occur at the first day after inguinal hernia repair in 25% of patients at
      rest and in 60% during activity. On day 6 after the operation the incidence can be as high as
      11% at rest and 33% during activity.

      Ultrasound imaging for regional anesthesia techniques have improved the success and safety
      rate of nerve blocks. We hypothesized that a procedure consisting of an ultrasound-guided
      inguinal field block (genitofemoral, iliohypogastric and ilioinguinal nerve block and
      incision line infiltration) could effectively control postoperative pain compared to
      selective unilateral subarachnoid anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity.</measure>
    <time_frame>Up to 24 hours.</time_frame>
    <description>Postoperative pain will be assessed by numeric ranking scale (numeric ranking scale NRS 0 to 10 points) at rest (static numeric ranking scale NRS) and during activity (dynamic numeric ranking scale NRS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Supplemental local anesthesia infiltration</measure>
    <time_frame>During surgery, up to 2 hours.</time_frame>
    <description>If needed, surgeons can infiltrate tissues with 15 ml of ropivacaine 5 mg/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion to general anesthesia.</measure>
    <time_frame>During surgery, up to 2 hours</time_frame>
    <description>Patients will receive remifentanil adjusted to maintain spontaneous breathing and conscious sedation with a Ramsay score = 2 during surgery if modest pain (numeric ranking scale NRS &gt; 4 and agitation) is sustained. If remifentanil is not sufficient for restoring patient comfort, the block will be considered failed and the patient will be given general anesthesia with propofol and a Proseal Laryngeal Mask.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mPADSS (Post-Anesthesia Discharge Scoring System)</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Assessed at every evaluation time postoperatively. The modified Post-Anesthesia Discharge Scoring System (mPADSS) includes stable heart and respiratory rates, absence of excessive nausea and pain, no bleeding from the surgical site, and ability to walk without support.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic requirement</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Assessed at every evaluation time postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Assessed through the activities assessment questionnaire 7 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events.</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Assessed at every evaluation time and including surgical and anesthesiological related events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from the end of anesthesia to first micturition.</measure>
    <time_frame>Up to 24 hours.</time_frame>
    <description>Assessed at every evaluation time postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from the end of surgery to the first unassisted walking.</measure>
    <time_frame>Up to 24 hours.</time_frame>
    <description>Assessed at every evaluation time postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total intrahospital stay.</measure>
    <time_frame>Up to 24 hours.</time_frame>
    <description>Assessed at every evaluation time postoperatively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Inguinal Hernia</condition>
  <arm_group>
    <arm_group_label>Triple inguinal nerve block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ropivacaine 5 mg/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unilateral subarachnoid anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine 10 mg/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Triple inguinal nerve block.</intervention_name>
    <description>Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.</description>
    <arm_group_label>Triple inguinal nerve block</arm_group_label>
    <other_name>Regional anesthesia for the groin.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Unilateral subarachnoid anesthesia</intervention_name>
    <description>Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.</description>
    <arm_group_label>Unilateral subarachnoid anesthesia</arm_group_label>
    <other_name>Regional anesthesia for the groin.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI (Body mass index) &lt; 30

          -  Non severe liver, renal or cardiac disease

          -  No allergy or contraindications to any of the study drugs

          -  American Hernia Society Score type I-II-IV-V hernia

          -  No pain or chronic analgesic administration in the preoperative period

          -  No previous surgery of the inguinal region

          -  Normal coagulation parameters and platelet count (&gt; 100.000).

          -  Dicumarol and aspirin suspension for &gt; 7 days

          -  Correctly administrated premedication

          -  No systemic infections

          -  No contraindications to subarachnoid anesthesia

        Exclusion Criteria:

          -  BMI (Body mass index) &gt; 30

          -  Severe liver, renal or cardiac disease

          -  Allergy or contraindications to any of the study drugs

          -  American Hernia Society Score type III-VI-VII-0 hernia

          -  Pain or chronic analgesic administration in the preoperative period

          -  Previous surgery of the inguinal region

          -  Anormal coagulation parameters and platelet count (&lt; 100.000).

          -  No dicumarol and aspirin suspension for &gt; 7 days

          -  Incorrectly administrated premedication

          -  Systemic infections

          -  Contraindications to subarachnoid anesthesia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhirajr Mokini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Gerardo Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Mauricio Ingelmo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>San Gerardo Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <last_update_submitted>February 3, 2014</last_update_submitted>
  <last_update_submitted_qc>February 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera San Gerardo di Monza</investigator_affiliation>
    <investigator_full_name>Zhirajr Mokini M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

